Novel Oral Drug Formulations: Their Potential in Modulating Adverse Effects

Drug Safety

Volumn 10, Issue 3, 1994, Pages 233-266

  Florence, Alexander T ^a   Jani, Praful U ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; BROMOCRIPTINE; CLONIDINE; CYCLOSPORIN; DOXAZOSIN; FELODIPINE; GLYCERYL TRINITRATE; INDOMETACIN; IRON SALT; KETOTIFEN; LEVODOPA; LITHIUM; MESALAZINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PANCREAS ENZYME; PRAZOSIN; PROSTAGLANDIN DERIVATIVE; RITODRINE; SALAZOSULFAPYRIDINE; SALBUTAMOL; THEOPHYLLINE; VERAPAMIL;

CONFUSION; DRUG ABSORPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG SAFETY; DYSKINESIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SEIZURE; SUSTAINED RELEASE PREPARATION; TACHYCARDIA; TREMOR; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR AGENTS; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; FOOD; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINAL ABSORPTION; SAFETY; SUPPORT, NON-U.S. GOV'T;

EID: 0028208349     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199410030-00005     Document Type: Review

References (259)

1. Non-steroidal, anti-inflammatory drugs-the extending scope of gastrointestinal side effects
2. Optimal assessment of gastrointesinal side effect induced by nonsteroidal anti-inflammatory drugs
3. The preparation and evaluation of a tablet dosage form of cyclosporine in dogs
4. Disposition pharmacokinetics of bezafibrate in man
5. Pharmacokinetic profile of piroxicam-β-cyclodextrin
6. Biopharmaceutical optimisation of β-cyclodextrin inclusion compounds
7. Comparison of Voltaren SR 75 once daily with Voltaren 25mg EC three times a daily in the treatment of mild to moderate osteoarthritis of the knee and hip
8. Comparison of Voltaren SR 75 twice daily with Voltaren 50mg EC three times a daily in the treatment of mild to severe osteoarthritis of the knee and hip
9. Gangrene of Meckel’s diverticulum in pregnancy due to iron tablets
10. Drug formulation and oesophageal injury
11. Incidence of cardiac arrythmias in patients taking slow release terbutaline for asthma
12. Effect of the acute sublingual administration of ketanserin in hypertensive patients
13. Monitoring of lithium treatment through determination of lithium concentration
14. Anon. Nifedipine: a new life with GITs. Lancet 340: 1507–1508, 1992b
15. Steady-state pharmacokinetics of two sustained-release theophylline products during once-daily and twice-daily dosing
16. Pharmacokinetics of nifedipine derived from a new retard tablet formulation
17. A comparison of two formulations of indomethacin (Flexin Continus) in the treatment of rheumatoid arthritis
18. Efficacy and tolerability of diclofenac dispersible in patients with osteoarthrosis
19. Drug delivery systems of the 90’s: innovations in controlled release
20. 2-blockade in healthy subjects: comparative study of metoprolol OROS
21. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density and diameter of pellets
22. Gastrointestinal transit of pellet system in ileostomy subject and the effect of density
23. Controlled-release delivery systems for hormones: a review of their properties and current therapeutic use
24. Feldene melt formulation controversy
25. Fatal gastointestinal damage associated with the use of osmotic mini-pump indomethacin (Osmosin)
26. Galenical development of a new sustained-release theophylline pellet formulation for once-daily administration
27. Prolonged respiratory depression caused by slow release morphine
28. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol
29. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise
30. 51Cr labelled pellets of different densities
31. Delivery of drugs to the colon by means of a new microencaspsulated oral dosage form
32. Influence of the dissolution rate of lithium tablets on side effects
33. Development and testing of bioadhesive fluoride containing slow-release tablets for oral use
34. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel
35. Pharmacokinetic determinants in the design and evaluation of sustained-release dosage forms
36. Gastrointestinal mucosal lesions: a drug formulation problem
37. A polymeric drug for treatment of inflammatory bowel disease
38. The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatine-capsule formulations
39. High strength pancreatic enzyme supplements and large bowel stricture in cystic fibrosis
40. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time
41. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine
42. The influence of infusion rate on the hemodynamic effects of felodipine
43. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract in patients with osteoarthritis
44. Pharmacokinetic comparison of a slow-release clonidine with conventional formulation after acute and chronic administration in hypertensives
45. Slow channel blockers
46. A study to compare the single dose and steady state pharmacokinetic profile and cardiovascular effects of nifedipine LA 60mg in elderly and young volunteers. Abstract
47. The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy
48. Transit of pharmaceutical dosage forms through the small intestine
49. The effect of density on the gastric empting of single and multiple unit dosage forms
50. Intestinal perforation associated with osmotic slow release indomethacin capsules
51. Bioadhesive dosage form for peroral administration of timolol base
52. Influence of food on the absorption of theophylline administered in the form of sustained-release tablets and microgranules
53. The influence of density on the gastrointestinal transit of pellets
54. Hydrogels for buccal drug delivery: properties relevant for muco-adhesion
55. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine
56. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high dose by mouth
57. An oral preparation to release drugs in the human colon
58. Comparative study of once and 3 times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia
59. Placebo-Kontrollieste doppelblinde 13-Center-Studie zum Nachweis des Therapeutischen Wirksam heit von Iloprost bei Patienten mit asterielles Verschlusskrankheit
60. Tolerability and well-being with metaprolol in a controlled release (CR/ZOK) formulation: a review article
61. Controlling drug effects through improved oral formulations
62. Thrombocytopaenia due to slow release oxprenolol
63. Effect of simultaneuosly ingested milk on phenytoin bioavailability
64. Relevance of pH dependency on in vitro release of bromocriptine from a modified-release formulation
65. Pharmaceutical and medical aspects of bioadhesive systems for drug administration
66. Felodipine clinical pharmacokinetics
67. The osmotic pump: novel research tool for optimizing drug regimens
68. Lithium absorption: implications for sustained-release lithium preparations
69. Reduction in the ulcerogenicity of naproxen by complexation with β-cyclodextrin
70. Biopharmaceutical aspects of ritodrine retard in pregnant women
71. Investigation of drug absorption from the gastrointestinal tract of man: influence of food and digestive secretions on metoprolol jejunal absorption
72. Formulation and dosage form design in drug-induced topical irritation of the gastrointestinal tract
73. Perforations of small bowel due to slow release potasium chloride (Slow-K)
74. Safety and tolerability of metoprolol OROS in hypertension treatment
75. Osmosin tablets
76. Sustained release theophylline preparation: pitfalls in generic prescribing
77. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. S.T.P
78. Comparative efficacy, safety and pharmacokinetics of Verapamil SR vs Verapamil IR in hypertensive patients
79. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients
80. A double blind study to evaluate the efficacy and tolerability of bronchial asthma
81. Sustained release theophylline preparations: practical recommendations for prescribing and therapeutic drug monitoring
82. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients
83. 111 Inmarked extended-release coated spheres
84. Evidence for site-specific absorption of novel ACE inhibitor
85. Minocycline toxicity: experience with an altered dosage regimen
86. Binding of acrylic polymers to mucin/epithelial surfaces: structure/property relationships
87. Clinical pharmacokinetics of iron preparations
88. Development of enzymatically degradable protective coatings for use in triggered drug delivery systems: derivatized starch hydrogels
89. Theophylline: a state of the art review
90. A clinical and pharmacokinetic basis for the selection and use of slow-release theophylline products
91. Absolute bioavailability of oral theophylline
92. Food induced ‘dose dumping’ from once-a-day theophylline product as a cause of theophylline toxicity
93. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained release niacin
94. Oral iloprost in healthy volunteers
95. Acute hepatic failure associated with the use of low-dose sustained release niacin
96. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man
97. Clonidine hydrochloride: review of pharmacologic and clinical aspects
98. Cecal vitamin bezoar formation inducing abdominal discomfort
99. Hollow fibres as an oral sustained-release delivery system
100. Albuterol extended-release products: a comparison of steady-state pharmacokinetics
101. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson’s disease
102. Current concepts in clinical therapeutics: asthma
103. Perforated jejunal diverticulum due to local iron toxicity
104. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients
105. The uptake and translocation of latex nanospheres and microspehres after oral adminstration to rats
106. Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat
107. Food interactions with sustained release theophylline preparations: a review
108. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations
109. Bioadhesive polymer systems for peptide delivery
110. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis
111. Gastric empting rates of drug preparations II. Effects of size and density of enteric-coated drug preparations and food on gastric empting rates in humans
112. Sustained-release verapamil as a first step drug treatment of mild to moderate hypertension
113. 1 analog in rats and dog
114. Slow release delivery of rioprostil by an osmotic pump inhibits the formulation of acute aspirin-induced gastric lesion in dogs and accelerated the healing of chronic lesions without incidence of side effects
115. On the intestinal transit of a single non-disintegrating object
116. Long term therapeutic efficacy with once daily isosorbide 5-mono-nitrate (Imdur®)
117. Controlled-Release metoprolol: clinical pharmacokinetic and therapeutic implications
118. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans
119. Nifedipine: kinetics and dynamics in healthy subjects
120. Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system
121. Development of multiple unit drug delivery system for positioned release in the gastrointestinal tract
122. How accurately can Parkinson’s disease be diagnosed?
123. Initiating treatment of Parkinson’s disease
124. Controlled biodegradability of polymers — a key to drug delivery systems
125. Are theophylline levels a reliable indicator of compliance
126. Therapeutic management of cystic fibrosis
127. An endoscopic comparison of the gastroduodenal injury with salsalate and naproxen
128. Gastro-intestinal transit time in human pregnancy: prolongation in the second and third trimesters followed by post-partum normalization
129. Comparative pharmacokinetics of 400mg bezafibrate after a single oral administration of a new slow-release preparation and currently available commercial form
130. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
131. Gastrointestinal lesions and potassium chloride supplements
132. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa
133. Chronopharmacokinetics and cardiovascular effects of nifedipine
134. Controlled release of nifedipine from gelatin microspheres and microcapsules: in vitro kinetics and pharmacokinetics in man
135. Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastointestinal problems
136. The effect of food and bile acid administration on the relative bioavailability of cyclosporin
137. Adverse reaction reviews
138. Influence of indomethacin amphoteric gel on gastric ulcerogenicity and absorption of indomethacin in rats
139. Alterations in the oral mucosa caused by chemotherapeutic agents
140. Controlled release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline
141. Evaluation of slow-release clonidine preparation by direct continuous blood pressure recording in essential hypertensive patients
142. Microencapsulation of terbutaline sulphate by the solvent evaporation technique
143. A multicenter, double-blind study on slow-release bromocriptine in the treatment of Parkinson’s disease
144. Neurotransmitters and CNS disease: basal ganglia disease
145. A clinical study on the prolonged antihypertensive effect of clonidine in a sustained-release capsule formulation
146. Protective effects of cyclodextrin on the local irritation induced by aqueous preparation of flurbiprofen
147. Current concepts: selective drug delivery systems
148. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial
149. Ketotifen in the prophylaxis of extrinsic bronchial asthma: a multicenter controlled double-blind study with a modified-release formulation
150. Comparison of conventional and sustained release bezafibrate in hyperlipidaemic patients
151. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety
152. Effectiveness and long-term tolerability slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia
153. Catapres Perlongets in the management of hypertension
154. Clinical and pharmacological study of a novel controlled release preparation of salbutamol
155. Acute overdose with sustained-release drug formulations: perspectives in treatment
156. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hyperlipidaemia
157. Pharmacokinetics and pharmacodynamics of levodopa
158. Sustained release nifedipine formulations
159. The effect of dosage regimen on the diuretic efficacy of chlorothiazide in human subjects
160. Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients
161. The bioavailability of sustained release nicotinic acid formulations
162. Assessment of in vivo drug dissolution by means of numerical deconvolution considering gastrointestinal availability
163. High strength pancreatic enzyme supplements and large bowel stricture in cystic fibrosis
164. Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subject
165. Prophylactic nitrate therapy in angina pectoris — is there an optimal treatment regimen?
166. The bilayer floating capsules: a stomach-directed drug delivery system for misoprostol
167. Lithium absorption from ordinary and sustained-release tablets
168. Gastrointestinal manifestations of cystic fibrosis: a review
169. Nitrate tolerance — can it be prevented
170. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. N-Cap study group
171. Pharmacokinetics of nifedipine
172. Edoscopic comparison of solid and liquid potassium chloride supplements
173. A model of dissolution-controlled solute release from porous drug delivery polymeric systems
174. Surface interfacial and molecular aspects of polymer bioadhesion on soft tissues
175. Optimization of levodopa therapy
176. Controlled release metoprolol formulations: a review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease
177. Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild to moderate hypertension
178. Nifedipine GITS (Gastrointestinal Therapeutic System) bezoar
179. Release kinetics of salbutamol sulphate from wax coated microcapsules and tableted microcapsules
180. Overdoses of sustained-release verapamil
181. Pathogenesis of adverse drug reactions
182. Implantable Osmotically powered drug delivery system
183. Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms
184. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution
185. Comparison of delayed-release 5-aminosalicylate (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis
186. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease
187. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine
188. The use of Sinemet CR in the management of mild to moderate Parkinson’s disease
189. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson’s disease
190. Microbially controlled drug delivery to the colon
191. In vitro evaluation of calcium pectinate: a potential colon specific drug delivery carrier
192. Newer pharmacologic agents for the therapy of inflammatory bowel disease
193. Extended levodopa release from a subcutaneously implanted polymer matrix in rats
194. Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats
195. A new approach to the oral administration of insulin and other peptide drugs
196. The rationale for continuous dopaminergic stimulation in patients with Parkinson’s disease
197. Comparative bioavailability of slow release diclofenac with enteric coated tablet and internationally used Voltaren retard
198. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/Zok: review article
199. Steady-state bioavailability and day to day variability of a multiple unit (CR/ZOK) and a single unit (OROS) delivery system of metoprolol after once daily dosing
200. Evaluation of the effect of food and specific gravity of tablets on gastric retention time
201. The effect of aging on the disposition of nifedipine and atenolol
202. An intra-oral drug delivery system
203. Hazards of slow-release preparations in patients with bowel strictures
204. Biochemical and mechanical characterization of enzyme-digestible hydrogels
205. TNj: a novel drug delivery system for oral use
206. The haemodynamic and anti-ischaemic effects of a single tablet of 80mg isosorbide dinitrate in slow-release formulations and a review of nitrate tolerance
207. Current concepts: nitroglycerin and long-acting nitrates
208. Endoscopic removal of pharmacobezoar of slow release theophylline
209. Strictures of ascending colon in cystic fibrosis and high strength pancreatic enzymes
210. Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind crossover comparison with conventional formulation in chronic schizophrenics
211. Oral absorption of nitrendipine in healthy subjects: a kinetic and dynamic study
212. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders
213. Massive ingestion of sustained-release verapamil with concretion and bowel infarction
214. Enhancement of methotrexate absorption by subdivision of doses
215. Treatment of hypertensive out-patients with sustained-release dosage form of Clonidine: a comparison with standard tablet therapy and long-term follow up study
216. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once evening administration
217. Cyclosporin induced nephrotoxicity: inevitable and intractable
218. Ulceration and stricture of the jejunum in a patient on long term indomethacin therapy
219. A pharmacokinetic study of mesalazine
220. Comparative evaluation of cardioselectivity of metoprolol OROS and atenolol: a double blind, placebo-controlled cross-over study
221. High strength pancreatic enzyme supplements and large bowel stricture in cystic fibrosis
222. Osmotic delivery systems for the β-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once daily administration
223. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease
224. Drug nutrient interactions
225. Cyclosporin absorption from microemulsion formulation in liver transplant recipient
226. Effect of food on nifedipine sustained-release preparation
227. Performance requirements for controlled-release dosage form: therapeutic and pharmacological perspectives
228. Rate-controlled drug dosage
229. Efficacy of lorazepam oral fast dissolving drug formulation (FDDF) in anesthesia premedication in adults: a double-blind placebo controlled comparison
230. Influence of food on the bioavailability of metoprolol from an OROS system: a study in healthy volunteers
231. CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers
232. Food-induced dose dumping of Theo-24, a once-daily slow-release theophylline product
233. Buccal and gastrointestinal drug delivery systems
234. Death from sustained release morphine sulphate
235. Bioadhesive polymer-grafted starch microspheres bearing isosorbide dinitrate for buccal administration
236. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis
237. A comparative study of standard and slow-release oral lithium carbonate products
238. Recent progress in protein and peptide delivery by noninvasive routes
239. Nicardipine sustained release in hypertension
240. Slow-release theophylline-rationale and basis for product selection
241. Effect of food on drug absorption
242. Respiratory depression after percutaneous cervical anterolateral cordotomy in patients on slow release oral morphine
243. Dysphagia caused by cardiac enlargement
244. Prostaglandin cyclo-oxygenase inhibition and its relationship to gastric damage
245. Relationship between systemic drug absorption and gastrointestinal transit after simultaneous oral administration of carbamazepine as a controlled release system and as a suspension of 15N-labelled drug to healthy volunteers
246. Assessment of disintegration and dissolution of dosage forms in vivo using gamma scitigraphy
247. Pharmacodynamics and tolerance of oral sustained release ritodrine
248. Pharmacokinetic overview of indomethacin and sustained release indomethacin
249. Drug-induced diseases: drug-induced gastro-intestinal disease